MedPath

Cognitive Behavioral Strategies and Transcranial Magnetic Stimulation in Obsessive-Compulsive Disorder: Open Label Study

Not Applicable
Terminated
Conditions
Obsessive Compulsive Disorder (OCD)
Interventions
Device: Transcranial magnetic stimulation
Behavioral: Cognitive behavioral therapy
Registration Number
NCT02528331
Lead Sponsor
Duke University
Brief Summary

The purpose of this study is to evaluate the effectiveness of repetitive TMS (rTMS) delivered simultaneously with elements of cognitive behavioral therapy/exposure-response prevention (CBT/ERP) in adult subjects (greater or equal to 18 years old) with obsessive-compulsive disorder (OCD). This is an open label study that involves standard of care for OCD (CBT) and an investigational treatment modality (TMS). The investigators will compare the Yale-Brown Obsessive Compulsive Scale (YBOCS) scores before and after treatment to quantify clinical improvement. The side effects from TMS include, but are not limited to, headache, seizure, and general pain. CBT has minimal side effects other than mental discomfort during the exposure sessions. For safety concerns, pregnant women and subjects with seizure-related history will be excluded as well as other indicated conditions in the details protocol.

Detailed Description

Not available

Recruitment & Eligibility

Status
TERMINATED
Sex
All
Target Recruitment
2
Inclusion Criteria

Not provided

Exclusion Criteria

Not provided

Study & Design

Study Type
INTERVENTIONAL
Study Design
SINGLE_GROUP
Arm && Interventions
GroupInterventionDescription
rTMS and Cognitive Behavior TherapyCognitive behavioral therapy-
rTMS and Cognitive Behavior TherapyTranscranial magnetic stimulation-
Primary Outcome Measures
NameTimeMethod
Remission Rate, as Measured by Y-BOCS6 weeks

Remission is defined as end-point Yale-Brown Obsessive Compulsive Scale (Y-BOCS) score less than the value of 16.

Secondary Outcome Measures
NameTimeMethod
Percentage of Adverse Events6 weeks
Partial Response Rate, as Measured by Y-BOCS6 weeks

Partial response is defined as a reduction of greater than 25%.

Complete Response, as Measured by Y-BOCS6 weeks

Complete response is defined as a reduction of Y-BOCS score greater than 35%.

Trial Locations

Locations (1)

Duke University Medical Center

🇺🇸

Durham, North Carolina, United States

© Copyright 2025. All Rights Reserved by MedPath